Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1976 1
1991 1
1996 2
1997 2
1998 3
1999 2
2001 2
2002 4
2003 4
2004 1
2005 9
2006 8
2007 16
2008 11
2009 17
2010 30
2011 25
2012 22
2013 18
2014 18
2015 22
2016 23
2017 17
2018 13
2019 22
2020 15
2021 15
2022 6
2023 5
2024 19
2025 23
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

321 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. Among authors: chae ys. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, Saura C, Schneeweiss A, Toi M, Chae YS, Kemal Y, Chaudhari M, Şendur MAN, Yamashita T, Casalnuovo M, Danso MA, Liu J, Shetty J, Herbolsheimer P, Loibl S; DESTINY-Breast09 Trial Investigators. Tolaney SM, et al. Among authors: chae ys. N Engl J Med. 2025 Oct 29. doi: 10.1056/NEJMoa2508668. Online ahead of print. N Engl J Med. 2025. PMID: 41160818
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.
Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. Mukohara T, et al. Among authors: chae ys. Nat Med. 2024 Aug;30(8):2242-2250. doi: 10.1038/s41591-024-03060-0. Epub 2024 Jun 1. Nat Med. 2024. PMID: 38824244 Free PMC article. Clinical Trial.
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.
Yamashita T, Sohn JH, Tokunaga E, Niikura N, Park YH, Lee KS, Chae YS, Xu B, Wang X, Im SA, Li W, Lu YS, Aguilar CO, Nishijima S, Nishiyama Y, Sugihara M, Modi S, Tsurutani J. Yamashita T, et al. Among authors: chae ys. Breast Cancer. 2024 Sep;31(5):858-868. doi: 10.1007/s12282-024-01600-7. Epub 2024 Jun 17. Breast Cancer. 2024. PMID: 38884900 Free PMC article. Clinical Trial.
Age- and ethnic-driven molecular and clinical disparity of East Asian breast cancers.
Lee JY, Lee JW, Chung MS, Choi JG, Sim SH, Kim HJ, Kim JE, Lee KE, Park YH, Kang MJ, Ahn MS, Chae YS, Park JH, Kim JH, Kim GM, Byun JH, Park KU, Kim JW, Jung SP, Lee JH, An JS, Jang B, Yoon D, Kim J, Hong J, Koo H, Cho KR, Kim CY, Sa JK, Park KH. Lee JY, et al. Among authors: chae ys. BMC Med. 2024 Sep 27;22(1):422. doi: 10.1186/s12916-024-03638-y. BMC Med. 2024. PMID: 39334392 Free PMC article.
The Role of EMP2 in Triple-negative Breast Cancer.
Lee IH, Kim EA, Lee SJ, Kang B, Lee J, Jung JH, Park HY, Park JY, Park NJ, Kang J, Chae YS. Lee IH, et al. Among authors: chae ys. Anticancer Res. 2025 Jun;45(6):2417-2427. doi: 10.21873/anticanres.17613. Anticancer Res. 2025. PMID: 40425330
Long non-coding RNA SOX2OT in tamoxifen-resistant breast cancer.
Lee J, Kim EA, Kang J, Chae YS, Park HY, Kang B, Lee SJ, Lee IH, Park JY, Park NJ, Jung JH. Lee J, et al. Among authors: chae ys. BMC Mol Cell Biol. 2024 Apr 22;25(1):12. doi: 10.1186/s12860-024-00510-y. BMC Mol Cell Biol. 2024. PMID: 38649821 Free PMC article.
321 results